Effects of Subconjunctival Bevacizumab on Corneal Neovascularization: Results of a Prospective Study
Effects of Subconjunctival Bevacizumab on Corneal Neovascularization: Results of a Prospective Study
复制标题
DOI：
10.1097/ico.0b013e31823f8d71
复制
发表时间：
2012-08-01
期刊：
影响因子：
2.8
通讯作者：
Robert, Pierre-Yves
中科院分区：
文献类型：
--
作者：
Benayoun, Yohan;Adenis, Jean-Paul;Robert, Pierre-Yves
目的：评估结膜下注射贝伐单抗对不同眼表疾病引起的角膜新生血管患者的效果。方法：前瞻性病例系列。纳入11例角膜新生血管患者的12只眼睛，其原因包括不同的眼表疾病，如愈合的角膜溃疡、长期存在的慢性炎症性疾病、烧伤继发的角膜缺血等。所有眼睛均接受单次结膜下注射 2.5 mg（0.1 mL）贝伐单抗。使用裂隙灯生物显微镜、角膜数码摄影和计算机辅助半自动分析角膜新生血管区域来评估3个月内新生血管的形态变化。结果：注射后1周，所有眼睛均观察到角膜血管退缩。新生血管树的表面在 1 个月内持续显着减少，然后在后续的剩余时间内再次增加。注射前角膜新生血管面积占角膜表面的 11.25 +/- 4.49%，而注射后为 8.44 +/- 3.37%（P = 0.02），反映出角膜新生血管平均减少了 25%。未观察到可能与结膜下注射贝伐单抗相关的局部或全身不良事件。结论：短期结果表明，结膜下注射贝伐单抗可安全有效地用于治疗不同眼表疾病引起的角膜新生血管，为提高角膜移植成功率提供了另一种策略。
Purpose: To evaluate the effect of subconjunctival bevacizumab injections in patients with corneal neovascularization resulting from different ocular surface disorders.Methods: Prospective case series. Twelve eyes of 11 patients with corneal neovascularization caused by different ocular surface disorders, such as healed corneal ulcers, long-standing chronic inflammatory diseases, and corneal ischemia secondary to burn, were included. All eyes received a single subconjunctival injection of 2.5 mg (0.1 mL) of bevacizumab. Morphological changes in neovascularization were evaluated during 3 months using slit-lamp biomicroscopy, corneal digital photography, and computer-assisted semiautomatic analysis of corneal neovascularization area.Results: Recession of corneal vessels was observed in all eyes at 1 week postinjection. The surface of the neovascular tree continued to decrease noticeably for 1 month and then increased again for the remainder of the follow-up period. The corneal neovascularization area amounted to 11.25 +/- 4.49% of the corneal surface preinjection, compared with 8.44 +/- 3.37% postinjection (P = 0.02), reflecting a mean decrease in corneal neovascularization of 25%. No local or systemic adverse events possibly related to subconjunctival bevacizumab injection were observed.Conclusions: Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.